Even so, the authors warned that the patients included in the meta-analysis of over 5,400 individuals -- drawn from the ...

A 70-year-old man was taken to the emergency room due to sudden difficulty in breathing. The diagnostic result is 'Closed ...

Daiichi Sankyo has launched its Lixiana product onto the UK market, where it becomes the fourth novel oral anti-coagulant (NOAC) available to treat and prevent clot-related disorders.

Dabigatran 110 mg twice daily was associated with significantly lower major bleeding risk than rivaroxaban 15 mg (OR: 0.18; 95% CI: 0.04–0.76). Additionally, rivaroxaban 10 mg and edoxaban 15 mg ...

This analysis highlights the potential for tailoring anticoagulant therapy in elderly AF patients, with edoxaban 15 mg and rivaroxaban 10 mg emerging as promising options. However, results should be ...

The EPIC-CAD Trial July 2, 2025 | Gi-Byoung Nam, Duk-Woo Park, and C. Michael Gibson weigh edoxaban monotherapy vs dual antithrombotic therapy for patients with AF and stable coronary artery disease.

Financial Valuation Company is profitable The company's revenue grew in March quarter by 10.11% from Rs 465.85 crore to Rs 423.07 crore, year-on-year The company's profit declined by 28.16% year ...

Hengstenberg C, Van Mieghem NM, Wang R, Ye X, Shi L, Guo S, Chen C, Jin J, Ye X, Dangas G, et al. Treatment satisfaction and convenience for patients with atrial fibrillation on edoxaban or vitamin K ...